Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company”…
Sagtec Global Limited Strengthens Smart Property Development Collaboration Following Stateight Sdn Bhd’s Industry Recognition
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals
MK International Achieves ASEAN & Asia Records for Proprietary Quantum Molecular Technology Spray Series
American Aires Inc. Announces Updates on Annual Filings, Litigation and Listing Matters, Cease Trade Order, and 2024 Financial Statements